A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis

Andrew Eisen, Benjamin M. Greenberg, James D. Bowen, Douglas L. Arnold, Anthony O. Caggiano

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis'. Together they form a unique fingerprint.

Medicine & Life Sciences